Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study

Table 3 Univariate analysis of overall survival in patients with bone metastasis of gene mutation-negative non-small cell lung cancer

Characteristic	n	Median OS	95%CI	P value
Age				0.51
≥ 70	23	14	7-not censored
< 70	22	19	10–54
Sex				0.72
Male	29	15	8–33
Female	16	16	8-not censored
Histological type				0.47
Adenocarcinoma	37	16	10–54
Others	8	14	1-not censored
Brain metastases				0.35
Yes	8	33	3–33
No	37	14	8–19
Adrenal metastasis				0.85
Yes	4	Not censored	4-not censored
No	41	16	8–33
ECOG PS				0.0079
≥ 2	16	8	3–33
≤ 1	29	19	13-not censored
Treatment before bone metastasis diagnosis				0.39
Yes	19	16	8-not censored
No	26	14	8–54
Chemotherapy before bone metastasis diagnosis				0.89
Yes	21	14	8–54
No	24	16	7–33
ICI use after bone metastasis diagnosis				0.031
Yes	28	22	8-not censored
No	17	13	5–16
Use of bone-modifying agent after bone metastasis diagnosis				0.027
Yes	36	16	12–54
No	9	5	2–33
Albumin				0.63
> 3.5	25	16	10-not censored
≤ 3.5	20	16	5–54
C-reactive protein				0.72
≥ 0.4	33	16	7–33
< 0.4	12	15	8-not censored
Lactate dehydrogenase				0.83
≥ 225	25	16	5–33
< 225	20	15	8–54
White blood cells				0.22
> 8500	20	14	5–22
≤ 8500	25	16	10–54
Neutrophil-to-lymphocyte ratio				0.47
≥ 5.0	21	16	8–33
< 5.0	24	15	8-not censored
Platelet-to-lymphocyte ratio				0.93
≥ 185	35	16	10–33
< 185	10	15	3–54

OS: Overall survival; ECOG PS: Eastern Cooperative Oncology Group performance status; ICIs: Immune checkpoint inhibitors.